For instance, it has been shown that Nrf2 pathway activation can repress gluconeogenesis and lipogenesis in liver and prevent fatty liver disease and ameliorate glycemic control in mouse models of obesity and insulin resistance [27,28]. The gene discussed is NFE2L2; the disease is obesity due to melanocortin 4 receptor deficiency.